Silvercrest Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Silvercrest Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-256,756	Closed	-$2.61M	–	813
2022 Q1	$2.61M	Buy	256,756 +3,030	+1%	+$31.1K	0.02%	464
2021 Q4	$4.23M	Buy	253,726 +179,992	+244%	+$7.62M	0.03%	405
2021 Q3	$3.46M	Buy	73,734 +27,425	+59%	+$1.47M	0.02%	428
2021 Q2	$2.82M	Buy	46,309 +1,061	+2%	+$60.6K	0.02%	454
2021 Q1	$2.79M	Sell	45,248 -35,422	-44%	-$2.32M	0.02%	450
2020 Q4	$5.74M	Sell	80,670 -12,872	-14%	-$621K	0.04%	345
2020 Q3	$3.51M	Buy	+93,542	New	+$2.94M	0.03%	391

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Silvercrest Asset Management's BBIO Position: Q2 2022 in Review

Silvercrest Asset Management sold out of BridgeBio Pharma (BBIO) in Q2 2022, closing a stake of 256,756 shares — an estimated $2.61M sold.

Silvercrest Asset Management first reported a position in BBIO in Q3 2020 and held it in 7 quarters. The position peaked at $5.74M in Q4 2020. 164 funds tracked by Wall St. Rank hold BBIO as of Q2 2022.

Silvercrest Asset Management reported no remaining BridgeBio Pharma position as of Q2 2022 after selling out during the quarter.
Silvercrest Asset Management sold 256,756 BridgeBio Pharma shares in Q2 2022, an estimated $2.61M.
Silvercrest Asset Management first reported a position in BridgeBio Pharma in Q3 2020 and held it in 7 quarters.
Silvercrest Asset Management's BridgeBio Pharma position peaked at $5.74M in Q4 2020.
164 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2022.

Based on Silvercrest Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.